Life Science Leader published an article by EVQLV's CEO, Andrew Satz, on how AI can be used in pharma to automate, analyze, or accelerate tasks as well as how to leverage AI to assist and augment team members. Written for leaders in the biotech and pharmaceutical...
EVQLV CEO, Andrew Satz, recently joined the Amplifying Scientific Innovation podcast with Dr. Sophia Ononye-Onyia. They discussed his definition of scientific innovation, personal anecdotes of his CEO journey and EVQLV's unique approach to scientific innovation...
As I mentioned in my previous post, our CEO, Andrew Satz, recently spoke at "Alumni in Conversation," hosted by Columbia University School of General Studies. During the discussion, Andrew explained how EVQLV's algorithm models the drug discovery process. See below....
I was recently watching BioIDEA’s Biotech vs COVID-19 event. During the event our CEO, Andrew Satz, was asked about the viability of fully computational drug discovery and development. His answer surprised me. He discussed a number of legitimate hurdles that need to...
Our CEO, Andrew Satz, recently spoke at Columbia University School of General Studies' "Alumni in Conversation." The subject of his talk was artificial intelligence. One of the questions posed to Andrew was what we were doing outside of coronavirus, along with the...
NEW YORK, NY and SOUTH SAN FRANCISCO, Calif – July 7, 2020 -- EVQLV, Inc., an artificial intelligence-enabled technology company accelerating biologics discovery, announced today a collaboration with Twist Bioscience Corporation (NASDAQ: TWST), a company enabling...
https://youtu.be/qIW1o8jgRsk Our technology works by taking an antibody sequence of interest and performing evolutionary modeled mutagenesis, mimicking the natural selection inherent to antibody VDJ recombination and affinity maturation. Using large amounts of public...
EVQLV's CEO, Andrew Satz, joined Kerrin Black of the Talent Finders Podcast to discuss his entrepreneurial journey, some of the challenges facing AI for drug discovery, his legacy and much more. Give it a listen below. https://youtu.be/A2QoFVnD1Wc Timestamps: Andrew's...
Our CEO was recently asked how far away is fully computational drug discovery and development. This isn't an easy question to answer and Andrew doesn't provide an exact date. However, he does provide interesting insight into the progress we've made and the challenges...
We recently held an event with BioIDEA: Biotech vs COVID-19. During the event, our CEO, Andrew Satz, was asked the value of computational drug discovery beyond just speed. Andrew explained that while speed is important, it can also be dangerous, and is certainly not...